Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A H Balk

Showing results (31-40 of 144) with videos related to

Pageof 15
Sort By:
Transplantation Proceedings|February 1, 1990
Passive immunization to prevent cytomegalovirus disease after kidney and heart transplantationW Weimar, H J Metselaar, A H Balk, et al.
American Journal of Nephrology|January 1, 1994
Time course of the decline in renal function in cyclosporine-treated heart transplant recipientsR Zietse, A H Balk, M A vd Dorpel, et al.
Transplantation Proceedings|February 1, 1989
Prophylactic use of anti-CMV immunoglobulins in heart transplant recipients: a study on its safetyH J Metselaar, J Velzing, P H Rothbarth, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 1, 1996
The intragraft cytokine mRNA pattern reflects the efficacy of steroid antirejection therapyC C Baan, H G Niesters, A H Balk, et al.
Nederlands Tijdschrift Voor Geneeskunde|February 15, 1997
[Successful heart transplantation in long-term ventilated patients]J J Bredée, A H Balk, N de Jonge, et al.
European Heart Journal|September 17, 1999
Cardiac peptides differ in their response to exercise. Implications for patients with heart failure in clinical practiceJ A Wijbenga, A H Balk, F Boomsma, et al.
Transplantation Proceedings|December 1, 1996
CsA therapy affects the direct and indirect antigen-presentation pathway in cardiac allograft recipientsN M van Besouw, L M Vaessen, A H Balk, et al.
Transplantation|May 15, 1997
Donor-specific cytokine production by graft-infiltrating lymphocytes induces and maintains graft vascular disease in human cardiac allograftsN M van Besouw, C R Daane, L M Vaessen, et al.
Transplant Immunology|June 2, 2000
Donor-derived soluble HLA plasma levels can not be used to monitor graft rejection in heart transplant recipientsC A Koelman, L M Vaessen, A H Balk, et al.
Transplantation|August 27, 1996
Progressive accumulation of CTL with high avidity for donor antigens during the development of acute cardiac rejectionN E van Emmerik, L M Vaessen, A H Balk, et al.
Pageof 15

Showing results (31-40 of 144) with videos related to

Sort By:
Pageof 15
Transplantation Proceedings|February 1, 1990
Passive immunization to prevent cytomegalovirus disease after kidney and heart transplantationW Weimar, H J Metselaar, A H Balk, et al.
American Journal of Nephrology|January 1, 1994
Time course of the decline in renal function in cyclosporine-treated heart transplant recipientsR Zietse, A H Balk, M A vd Dorpel, et al.
Transplantation Proceedings|February 1, 1989
Prophylactic use of anti-CMV immunoglobulins in heart transplant recipients: a study on its safetyH J Metselaar, J Velzing, P H Rothbarth, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 1, 1996
The intragraft cytokine mRNA pattern reflects the efficacy of steroid antirejection therapyC C Baan, H G Niesters, A H Balk, et al.
Nederlands Tijdschrift Voor Geneeskunde|February 15, 1997
[Successful heart transplantation in long-term ventilated patients]J J Bredée, A H Balk, N de Jonge, et al.
European Heart Journal|September 17, 1999
Cardiac peptides differ in their response to exercise. Implications for patients with heart failure in clinical practiceJ A Wijbenga, A H Balk, F Boomsma, et al.
Transplantation Proceedings|December 1, 1996
CsA therapy affects the direct and indirect antigen-presentation pathway in cardiac allograft recipientsN M van Besouw, L M Vaessen, A H Balk, et al.
Transplantation|May 15, 1997
Donor-specific cytokine production by graft-infiltrating lymphocytes induces and maintains graft vascular disease in human cardiac allograftsN M van Besouw, C R Daane, L M Vaessen, et al.
Transplant Immunology|June 2, 2000
Donor-derived soluble HLA plasma levels can not be used to monitor graft rejection in heart transplant recipientsC A Koelman, L M Vaessen, A H Balk, et al.
Transplantation|August 27, 1996
Progressive accumulation of CTL with high avidity for donor antigens during the development of acute cardiac rejectionN E van Emmerik, L M Vaessen, A H Balk, et al.
Pageof 15